Adalimumab-atto, Fourth Biosimilar Approved by the FDA

Online First - FDA Approvals

On September 23, 2016, the US Food and Drug Administration (FDA) approved adalimumab-atto (Amjevita; Amgen) as a biosimilar to adalimumab (Humira; AbbVie) for the treatment of several indications and inflammatory diseases in adults, including moderate-to-severe rheumatoid arthritis; psoriatic arthritis; ankylosing spondylitis; moderate-to-severe Crohn’s disease; moderate-to-severe ulcerative colitis; and moderate-to-severe plaque psoriasis.

The new biosimilar is also indicated for the treatment of moderate-to-severe polyarticular juvenile idiopathic arthritis in patients aged ≥4 years.

“This is the fourth FDA-approved biosimilar. The biosimilar pathway is still a new frontier and one that we expect will enhance access to treatment for patients with serious medical conditions,” said Janet Woodcock, MD, Director of the FDA’s Center for Drug Evaluation and Research.

As in the case of the previous 3 biosimilars, adalimumab-atto is approved as a biosimilar, not as an interchangeable agent.

The approval of adalimumab-atto is based on review of evidence from human pharmacokinetic and pharmacodynamics data, clinical immunogenicity data, and other data demonstrating the clinical safety and effectiveness of this drug, showing that adalimumab-atto is indeed biosimilar to adalimumab.

The most common expected adverse events with adalimumab-atto are infections and injection-site reactions. This biosimilar carries a boxed warning about an increased risk for serious infections, as well as a warning that lymphoma and other malignancies have been reported in children and adolescent patients who received this type of drug.  

The third biosimilar, etanercept-szzs (Erelzi; Sandoz), was approved by the FDA on August 30, 2016, as a biosimilar to etanercept (Enbrel; Novartis) for the same indications as those approved for the reference drug.

The second biosimilar to receive FDA approval was infliximab-dyyb (Inflectra; Celltrio), a biosimilar to infliximab (Remicade; Janssen). Infliximab-dyyb was approved on April 5, 2016, for the same indications as its reference drug.

Related Items
Polivy FDA Approved for Patients with Relapsed or Refractory DLBCL
August 2019, Vol 12, Special Issue: Payers’ Perspectives In Oncology: ASCO 2019 Highlights published on August 16, 2019 in FDA Approvals
Xpovio Receives FDA Approval for Patients with Relapsed or Refractory Multiple Myeloma
August 2019, Vol 12, Special Issue: Payers’ Perspectives In Oncology: ASCO 2019 Highlights published on August 16, 2019 in FDA Approvals
Revlimid Approved for Patients with Follicular Lymphoma or Marginal-Zone Lymphoma
August 2019, Vol 12, Special Issue: Payers’ Perspectives In Oncology: ASCO 2019 Highlights published on August 16, 2019 in FDA Approvals
Keytruda First PD-1 Inhibitor Approved as First-Line Monotherapy for Patients with Metastatic or Unresectable Head and Neck Cancer
August 2019, Vol 12, Special Issue: Payers’ Perspectives In Oncology: ASCO 2019 Highlights published on August 16, 2019 in FDA Approvals
Keytruda Receives New Indication for Metastatic Small-Cell Lung Cancer After Disease Progression
August 2019, Vol 12, Special Issue: Payers’ Perspectives In Oncology: ASCO 2019 Highlights published on August 16, 2019 in FDA Approvals
Last modified: October 17, 2016
  •  Association for Value-Based Cancer Care
  • Oncology Practice Management
  • Value-Based Cancer Care
  • Value-Based Care in Rheumatology
  • Rheumatology Practice Management
  • Urology Practice Management
  • Lynx CME